Clinical trial · Observational
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation (Secondary Data Use Study of Dabrafenib-Trametinib in "Real Life" for Non-Small Cell Lung Cancer With a BRAF V600 Mutation)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
BLaDE cohort will evaluate overall survival (OS), real world progression-free survival (PFS), best response and duration of treatment in patients with advanced, metastatic Non-Small Cell Lung Cancer (NSCLC) harboring BRAF V600E or non E mutation who received dabrafeninb-trametinib combination or not. Subsequent or previous treatments (treatments delivered after or before dabrafeninb-trametinib combination will be recorded). Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BRAF V600 Mutation | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival (OS) at 12 months in non-small cell lung cancer (NSCLC) BRAF V600E-mutated patients receiving the combination of dabrafenib-trametinib as second line or more treatment
- timeFrame
- 12 months
- description
- OS will be determined as the time from the first dose of treatment with dabrafenib-trametinib to death from any cause
Secondary outcomes (5)
- measure
- OS at 18 and 24 months and median OS in NSCLC BRAF V600E-mutated patients receiving the combination of dabrafenib-trametinib as second line or more treatment
- timeFrame
- 18 and 24 months
- description
- OS will be determined as the time from the first dose of treatment with dabrafenib-trametinib to death from any cause
- measure
- OS at 12, 18 and 24 months and median OS in NSCLC BRAF V600E-mutated patients receiving the combination of dabrafenib-trametinib as first-line treatment
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically or cytologically confirmed extensive stage NSCLC * Presence of BRAF V 600 E or non E mutation diagnosed on tumor sample and/or on liquid biopsy (co mutations allowed) between 01/01/2016 and 31/12/2019 * Patients who received at least one dose of treatment with dabrafenib-trametinib combination (whatever the treatment line) * NSCLC BRAF V600 patients who have not received the dabrafenib-trametinib combination will be included for the collection of clinical and demographic data, treatments received and OS * Patients who were informed about the study and do not refused for their data to be collected and used * Age \> 18 years Exclusion Criteria: * Patients harboring a non V600 BRAF mutation * Patients enrolled in a clinical trial assessing treatment with dabrafenib-trametinib combination * Explicit refusal by the patient to collect his or her data * Patients under curatorship or guardianship * Unable to obtain data collection
References
Publications (0)
Data not yet available